Abstract
EPM1 is the most common form of Progressive Myoclonus Epilepsy characterized by late-childhood onset, ever-worsening and disabling myoclonus, seizures, ataxia, psychiatric disease, and shortened lifespan. EPM1 is caused by expansions of a dodecamer repeat sequence in the promoter of CSTB (cystatin B), which dramatically reduces, but does not eliminate, gene expression. The relatively late onset and consistent presence of a minimal amount of protein product makes EPM1 a favorable target for gene replacement therapy. If treated early, these children’s normally developed brains could be rescued from the neurodegeneration that otherwise follows, and their cross-reactive immunological material (CRIM) positive status greatly reduces transgene related toxicity. We performed a proof-of-concept CSTB gene replacement study in Cstb knockout mice by introducing full-length human CSTB driven by the CBh promoter packaged in AAV9 and administered at postnatal days 21 and 60. Mice were sacrificed at 2 or 9 months of age, respectively. We observed significant improvements in expression levels of neuroinflammatory pathway genes and cerebellar granule cell layer apoptosis, as well as amelioration of motor impairment. The data suggest that gene replacement is a promising therapeutic modality for EPM1 and could spare affected children and families the ravages of this otherwise severe neurodegenerative disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
All raw data used to prepare this manuscript is available upon contacting corresponding author.
References
Crespel A, Ferlazzo E, Franceschetti S, Genton P, Gouider R, Kalviainen R, et al. Unverricht-Lundborg disease. Epileptic Disord. 2016;18:28–37.
Lalioti MD, Scott HS, Buresi C, Rossier C, Bottani A, Morris MA, et al. Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature. 1997;386:847–51.
Joensuu T, Lehesjoki AE, Kopra O. Molecular background of EPM1-Unverricht-Lundborg disease. Epilepsia. 2008;49:557–63.
Mancini GM, Schot R, de Wit MC, de Coo RF, Oostenbrink R, Bindels-de Heus K, et al. CSTB null mutation associated with microcephaly, early developmental delay, and severe dyskinesia. Neurology. 2016;86:877–8.
O’Brien A, Marshall CR, Blaser S, Ray PN, Yoon G. Severe neurodegeneration, progressive cerebral volume loss and diffuse hypomyelination associated with a homozygous frameshift mutation in CSTB. Eur J Hum Genet. 2017;25:775–8.
Di Matteo F, Pipicelli F, Kyrousi C, Tovecci I, Penna E, Crispino M, et al. Cystatin B is essential for proliferation and interneuron migration in individuals with EPM1 epilepsy. EMBO Mol Med. 2020;12:e11419.
Pennacchio LA, Bouley DM, Higgins KM, Scott MP, Noebels JL, Myers RM. Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nat Genet. 1998;20:251–8.
Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358–78.
Lykken EA, Shyng C, Edwards RJ, Rozenberg A, Gray SJ. Recent progress and considerations for AAV gene therapies targeting the central nervous system. J Neurodev Disord. 2018;10:16.
Shannon P, Pennacchio LA, Houseweart MK, Minassian BA, Myers RM. Neuropathological changes in a mouse model of progressive myoclonus epilepsy: cystatin B deficiency and Unverricht-Lundborg disease. J Neuropathol Exp Neurol. 2002;61:1085–91.
Franceschetti S, Sancini G, Buzzi A, Zucchini S, Paradiso B, Magnaghi G, et al. A pathogenetic hypothesis of Unverricht-Lundborg disease onset and progression. Neurobiol Dis. 2007;25:675–85.
Husi H, Fernandes M, Skipworth RJ, Miller J, Cronshaw AD, Fearon KCH, et al. Identification of diagnostic upper gastrointestinal cancer tissue type-specific urinary biomarkers. Biomed Rep. 2019;10:165–74.
Tegelberg S, Kopra O, Joensuu T, Cooper JD, Lehesjoki AE. Early microglial activation precedes neuronal loss in the brain of the Cstb−/− mouse model of progressive myoclonus epilepsy, EPM1. J Neuropathol Exp Neurol. 2012;71:40–53.
Sanz P, Serratosa JM. Neuroinflammation and progressive myoclonus epilepsies: from basic science to therapeutic opportunities. Expert Rev Mol Med. 2020;22:e4.
Okuneva O, Korber I, Li Z, Tian L, Joensuu T, Kopra O, et al. Abnormal microglial activation in the Cstb(−/−) mouse, a model for progressive myoclonus epilepsy, EPM1. Glia. 2015;63:400–11.
Okuneva O, Li Z, Korber I, Tegelberg S, Joensuu T, Tian L, et al. Brain inflammation is accompanied by peripheral inflammation in Cstb (−/−) mice, a model for progressive myoclonus epilepsy. J Neuroinflammation. 2016;13:298.
Manninen O, Koskenkorva P, Lehtimaki KK, Hypponen J, Kononen M, Laitinen T, et al. White matter degeneration with Unverricht-Lundborg progressive myoclonus epilepsy: a translational diffusion-tensor imaging study in patients and cystatin B-deficient mice. Radiology. 2013;269:232–9.
Manninen O, Laitinen T, Lehtimaki KK, Tegelberg S, Lehesjoki AE, Grohn O, et al. Progressive volume loss and white matter degeneration in cstb-deficient mice: a diffusion tensor and longitudinal volumetry MRI study. PLoS One. 2014;9:e90709.
Sipila JOT, Hypponen J, Kyto V, Kalviainen R. Unverricht-Lundborg disease (EPM1) in Finland: a nationwide population-based study. Neurology. 2020;95:e3117–e23.
Norio R, Koskiniemi M. Progressive myoclonus epilepsy: genetic and nosological aspects with special reference to 107 Finnish patients. Clin Genet. 1979;15:382–98.
Paulson H. Repeat expansion diseases. Handb Clin Neurol. 2018;147:105–23.
Nitschke F, Ahonen SJ, Nitschke S, Mitra S, Minassian BA. Lafora disease - from pathogenesis to treatment strategies. Nat Rev Neurol. 2018;14:606–17.
Alakurtti K, Weber E, Rinne R, Theil G, de Haan GJ, Lindhout D, et al. Loss of lysosomal association of cystatin B proteins representing progressive myoclonus epilepsy, EPM1, mutations. Eur J Hum Genet. 2005;13:208–15.
Zerovnik E. Human stefin B: from its structure, folding, and aggregation to its function in health and disease. Front Mol Neurosci. 2022;15:1009976.
Kopitar-Jerala N. The role of stefin B in neuro-inflammation. Front Cell Neurosci. 2015;9:458.
Penna E, Cerciello A, Chambery A, Russo R, Cernilogar FM, Pedone EM, et al. Cystatin B involvement in synapse physiology of rodent brains and human cerebral organoids. Front Mol Neurosci. 2019;12:195.
Daura E, Tegelberg S, Yoshihara M, Jackson C, Simonetti F, Aksentjeff K, et al. Cystatin B-deficiency triggers ectopic histone H3 tail cleavage during neurogenesis. Neurobiol Dis. 2021;156:105418.
Xu TT, Zeng XW, Wang XH, Yang LX, Luo G, Yu T. Cystatin-B negatively regulates the malignant characteristics of oral squamous cell carcinoma possibly via the epithelium proliferation/differentiation program. Front Oncol. 2021;11:707066.
Lehtinen MK, Tegelberg S, Schipper H, Su H, Zukor H, Manninen O, et al. Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy, EPM1. J Neurosci. 2009;29:5910–5.
Ceru S, Konjar S, Maher K, Repnik U, Krizaj I, Bencina M, et al. Stefin B interacts with histones and cathepsin L in the nucleus. J Biol Chem. 2010;285:10078–86.
Chakrabarty P, Rosario A, Cruz P, Siemienski Z, Ceballos-Diaz C, Crosby K, et al. Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain. PLoS One. 2013;8:e67680.
Hollidge BS, Carroll HB, Qian R, Fuller ML, Giles AR, Mercer AC, et al. Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors. Front Neurol. 2022;13:1051559.
Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16:1073–80.
Reimsnider S, Manfredsson FP, Muzyczka N, Mandel RJ. Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol Ther. 2007;15:1504–11.
Chew NK, Mir P, Edwards MJ, Cordivari C, Martino D, Schneider SA, et al. The natural history of Unverricht-Lundborg disease: a report of eight genetically proven cases. Mov Disord. 2008;23:107–13.
Magaudda A, Ferlazzo E, Nguyen VH, Genton P. Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients. Epilepsia. 2006;47:860–6.
Eldridge R, Iivanainen M, Stern R, Koerber T, Wilder BJ. “Baltic” myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet. 1983;2:838–42.
Iivanainen M, Eldridge R. Effect of phenytoin on the mental and physical function of patients with Baltic myoclonus epilepsy. Ital J Neurol Sci. 1987;8:313–7.
Clement N, Grieger JC. Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol Ther Methods Clin Dev. 2016;3:16002.
Gray SJ, Choi VW, Asokan A, Haberman RA, McCown TJ, Samulski RJ. Production of recombinant adeno-associated viral vectors and use in in vitro and in vivo administration. Curr Protoc Neurosci. 2011;Chapter 4:Unit 4 17.
Sheehan DC, Hrapchak BB. Theory and practice of histotechnology, 2nd ed. Mosby; 1980.
Woods AEAE, Roy C. Laboratory histopathology, a complete reference. Churchill-Livingston Press; 1996.
Shelton JM, Grauer G, Richardson JA. Combination low magnification dark-field illuminator and bright-field microscopy substage condenser with descriptions and modifications to manufacture this device from commercially available fiber-optic ring lights, UTSD: 1494. 2003. http://www.utsouthwestern.edu/labs/molecular-pathology/about/intellectualproperty/utsd1494.html.
Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493–501.
Promega Technical Bulletin 235 (TB235). Instruction Booklet for Use of Product G3250. Madison WI, USA: Promega Corporation; 2008.
Acknowledgements
This work was funded by Ultragenyx and Hope for ULD. We thank the UT Southwestern Histopathology (Dr. John Shelton), Whole Brain Microscopy (Dr. Denise Ramirez), Rodent Behavior core (Dr. Shari Birnbaum) and Neuro-Models facility (Dr. Erik Plautz) for assistance with tissue processing, imaging, the rotarod test and video-electrocorticography, respectively. BAM holds the University of Texas Southwestern Jimmy Elizabeth Westcott Chair in Pediatric Neurology.
Author information
Authors and Affiliations
Contributions
BAM and EG designed the project. BAM wrote the manuscript. EG, SK, and MV conducted the experiments, analyzed the data, and helped write the manuscript. DVA, UM, and XC helped in parts of experiments. SFM, AL, and SJG provided feedback and reviewed the manuscript. BAM supervised the project.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Gumusgoz, E., Kasiri, S., Verma, M. et al. CSTB gene replacement improves neuroinflammation, neurodegeneration and ataxia in murine type 1 progressive myoclonus epilepsy. Gene Ther (2023). https://doi.org/10.1038/s41434-023-00433-x
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41434-023-00433-x